Fibrotic lung diseases in children.
antifibrotic
children
interstitial lung disease
nintedanib
pirfenidone
pulmonary fibrosis
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
14 Feb 2024
14 Feb 2024
Historique:
revised:
08
01
2024
received:
02
11
2023
accepted:
31
01
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
In children, pulmonary fibrosis (PF) is an extremely unusual entity that can be observed in some types of interstitial lung disease (ILD). Defining whether ILD is accompanied by PF is important for targeted therapy. Algorithm for the diagnosis of PF in children is not clearly established. Besides, the clinical, radiological, and histological definitions commonly used to diagnose particularly the cases of idiopathic PF in adult patients, is not applicable to pediatric cases. However, a few studies conducted in children offer good exemplary diagnostic approach to fibrosing ILD. Thorax high resonance computed tomography and/or lung biopsy scanning can provide valuable information about PF. Another issue that has not been clearly established is when to start antifibrotic treatment in pediatric patients with PF. The objective of this current review is to provide a comprehensive overview of pediatric PF by drawing upon adult research, particularly focusing on the areas of uncertainty.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : None
Informations de copyright
© 2024 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.
Références
DeBoer EM, Liptzin DR, Humphries SM, et al. Ground glass and fibrotic change in children with surfactant protein C dysfunction mutations. Pediatr Pulmonol. 2021;56(7):2223-2231.
Kornum JB, Christensen S, Grijota M, et al. The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study. BMC Pulm Med. 2008;8:24.
Clement A, Nathan N, Epaud R, Fauroux B, Corvol H. Interstitial lung diseases in children. Orphanet J Rare Dis. 2010;5:22.
Bhalla D, Jana M, Naranje P, Bhalla AS, Kabra SK. Fibrosing interstitial lung disease in children: an HRCT-based analysis. Indian J Pediatr. 2023;90(2):153-159.
Ionescu MD, Popescu NA, Stănescu D, et al. The challenging diagnosis of interstitial lung disease in Children-One case report and literature review. J Clin Med. 2022;11(22):6736.
Nayir-Buyuksahin H, Emiralioglu N, Kilinc AA, et al. Childhood interstitial lung disease in Turkey: first data from The National registry. Eur J Pediatr. 2023.
Nathan N, Sileo C, Thouvenin G, et al. Pulmonary fibrosis in children. J Clin Med. 2019;8(9):1312.
Thannickal VJ, Toews GB, White ES, Lynch III JP, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395-417.
Deterding RR, DeBoer EM, Cidon MJ, et al. Approaching clinical trials in childhood interstitial lung disease and pediatric pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(10):1219-1227.
Cerro Chiang G, Lee C, Marchevsky A, Lewis MI. Severe nonspecific interstitial pneumonia (NSIP) in an adolescent. Case Rep Pulmonol. 2022;2022:1-5.
Kligerman SJ, Groshong S, Brown KK, Lynch DA. Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations. Radiographics. 2009;29(1):73-87.
Zapletal A, Houštěk J, Šamánek M, Čopová M, Paul T. Lung function in children and adolescents with idiopathic interstitial pulmonary fibrosis. Pediatr Pulmonol. 1985;1(3):154-166.
Vece TJ, Fan LL. Interstitial lung disease in children older than 2 years. Pediatr Allergy Immunol Pulmonol. 2010;23(1):33-41.
Rice A, Tran-Dang MA, Bush A, Nicholson AG. Diffuse lung disease in infancy and childhood: expanding the chILD classification. Histopathology. 2013;63(6):743-755.
Young LR, Nogee LM, Barnett B, Panos RJ, Colby TV, Deutsch GH. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest. 2008;134(1):192-195.
Campo I, Zorzetto M, Mariani F, et al. A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. Respir Res. 2014;15(1):43.
Soares JJ, Deutsch GH, Moore PE, et al. Childhood interstitial lung diseases: an 18-year retrospective analysis. Pediatrics. 2013;132(4):684-691.
Fan LL, Dishop MK, Galambos C, et al. Diffuse lung disease in biopsied children 2 to 18 years of age. application of the chILD classification scheme. Ann Am Thorac Soc. 2015;12(10):1498-1505.
Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958-968.
Fainberg HP, Oldham JM, Molyneaux PL, et al. Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort. Lancet Digit Health. 2022;4(12):e862-e872.
Yokoyama T, Gochuico BR. Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease. Eur Respir Rev. 2021;30(159):200193.
Chung JH, Cox CW, Montner SM, et al. CT features of the usual interstitial pneumonia pattern: differentiating connective tissue Disease-Associated interstitial lung disease from idiopathic pulmonary fibrosis. Am J Roentgenol. 2018;210(2):307-313.
Salvatore M, Smith ML. Cross sectional imaging of pulmonary fibrosis translating pathology into radiology. Clin Imaging. 2018;51:332-336.
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68.
Matthias Griese ES, Knoflach Katrin, Ley-Zaporozhan Julia, et al. Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry. Eur Respir J. 2020;56(suppl 64):5257.
Deterding R, Young LR, DeBoer EM, et al. Nintedanib in children and adolescents with fibrosing interstitial lung diseases. Eur Respir J. 2023;61(2):2201512.
Meyer KC. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med. 2017;11(5):343-359.
Schütz K, Schmidt A, Schwerk N, et al. Variants in FGF10 cause early onset of severe childhood interstitial lung disease: a detailed description of four affected children. Pediatr Pulmonol. 2023;58(11):3095-3105.
Ono S, Tanaka T, Ishida M, et al. Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. Eur Respir J. 2011;38(4):861-869.
Griese M. Chronic interstitial lung disease in children. Eur Respir Rev. 2018;27(147):170100.
Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196(6):680-689.
Selman M, Pardo A, King Jr. TE Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012;186(4):314-324.
Mastrorilli C, Pecoraro L, Arasi S, et al. Pediatric hypersensitivity pneumonitis: literature update and proposal of a diagnostic algorithm. Ital J Pediatr. 2022;48(1):51.
García-Peña P, Boixadera H, Barber I, Toran N, Lucaya J, Enríquez G. Thoracic findings of systemic diseases at high-resolution CT in children. Radiographics. 2011;31(2):465-482.
Bush A, Cunningham S, de Blic J, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax. 2015;70(11):1078-1084.
Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol. 2015;50(4):410-419.
Williamson M, Wallis C. Ten-year follow up of hydroxychloroquine treatment for ABCA3 deficiency. Pediatr Pulmonol. 2014;49(3):299-301.
Jeremiah N, Neven B, Gentili M, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516-5520.
Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507-518.
Thouvenin G, Nathan N, Epaud R, Clement A. Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin. Case Reports. 2013;2013:bcr2013009988.
Guillot L, Tabary O, Nathan N, Corvol H, Clement A. Macrolides: new therapeutic perspectives in lung diseases. Int J Biochem Cell Biol. 2011;43(9):1241-1246.
Aravena C, Labarca G, Venegas C, Arenas A, Rada G. Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and Meta-Analysis. PLoS One. 2015;10(8):e0136160.
Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74-79.
Gundogan BD, Taskinlar S, Arikoglu T, Balci Y, Citak EC. Bleomycin-induced pneumonitis in a child treated with nintedanib: report of the first case in a childhood. J Pediatr Hematol Oncol. 2022;44(2):e500-e502.
Lasky JA, Criner GJ, Lazarus HM, Kohlbrenner V, Bender S, Richeldi L. Safety of nintedanib in patients with idiopathic pulmonary fibrosis: global pharmacovigilance data. Adv Ther. 2020;37(10):4209-4219.
Deng L, Chen Y, Hu X, Zhou J, Zhang Y. Case report: successful treatment of refractory interstitial lung disease with cyclosporine A and pirfenidone in a child with SLE. Front Immunol. 2021;12:708463.
Matteson EL, Aringer M, Burmester GR, Mueller H, Moros L, Kolb M. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial. Clin Rheumatol. 2023;42(9):2311-2319.
Tang W, Yu T, Dong T, Liu T, Ji J. Nintedanib in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Chest. 2020;158(3):e89-e91.
McKinzie CJ, Gower WA, Hagood JS, Vece TJ. Use of pirfenidone in pediatric patients with interstitial lung disease and pulmonary fibrosis. Pediatr Pulmonol. 2023;58(8):2396-2398.
Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4(1):e000212.
Abou Taam R, Jaubert F, Emond S, et al. Familial interstitial disease with I73T mutation: a mid- and long-term study. Pediatr Pulmonol. 2009;44(2):167-175.